UK markets closed

IDEAYA Biosciences, Inc. (IDYA)

NasdaqGS - NasdaqGS Real-time price. Currency in USD
Add to watchlist
43.88+0.57 (+1.32%)
At close: 04:00PM EDT
43.88 0.00 (0.00%)
After hours: 04:20PM EDT

IDEAYA Biosciences, Inc.

7000 Shoreline Court
Suite 350
South San Francisco, CA 94080
United States
650 443 6209
https://www.ideayabio.com

Sector(s)Healthcare
IndustryBiotechnology
Full-time employees124

Key executives

NameTitlePayExercisedYear born
Mr. Yujiro S. HataPresident, CEO & Director851.7kN/A1974
Dr. Michael A. White Ph.D.Chief Scientific Officer613.85kN/A1966
Dr. Darrin M. Beaupre M.D., Ph.D.Chief Medical Officer152.64kN/A1967
Mr. Andres Ruiz Briseno CPAPrincipal Accounting Officer, Senior VP and Head of Finance & Investor RelationsN/AN/A1987
Dr. Paul A. Barsanti Ph.D.Chief Technology OfficerN/AN/AN/A
Mr. Jason S. Throne Esq., J.D.Chief Legal Officer & Company Secretary425.56kN/A1972
Mr. Mick O'QuigleyChief of Staff & Clinical DevelopmentN/AN/AN/A
Amounts are as of 31 December 2022, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.

Description

IDEAYA Biosciences, Inc., a synthetic lethality-focused precision medicine oncology company, discovers and develops targeted therapeutics for patient populations selected using molecular diagnostics in the United States. The company's products in development include IDE196, a protein kinase C inhibitor that is in Phase 2/3 clinical trials for genetically defined cancers having GNAQ or GNA11 gene mutations; IDE397, a methionine adenosyltransferase 2a inhibitor that is in Phase 1/2 clinical trials for patients with solid tumors having methylthioadenosine phosphorylase gene deletions, such as non-small cell lung, bladder, gastric, and esophageal cancers; IDE161, a poly ADP-ribose glycohydrolase inhibitor that is in Phase 1 clinical trial to treat tumors with homologous recombination deficiency (HRD), and other genetic or molecular signatures; GSK101, a Pol Theta Helicase inhibitor that is in Phase 1 clinical trial for the treatment of tumors with BRCA or other homologous recombination, and HRD mutations; and Werner Helicase inhibitors for tumors with high microsatellite instability. It offers preclinical research programs focused on pharmacological inhibition; DECIPHER dual CRISPR library for synthetic lethality target and biomarker discovery; and INQUIRE chemical library and HARMONY machine-learning engines to enhance its drug discovery platform. The company has strategic alliances with GlaxoSmithKline, Pfizer Inc., Novartis International Pharmaceuticals Ltd., Amgen Inc., Gilead Sciences, Inc., Cancer Research UK, and the University of Manchester. IDEAYA Biosciences, Inc. was incorporated in 2015 and is headquartered in South San Francisco, California.

Corporate governance

IDEAYA Biosciences, Inc.’s ISS governance QualityScore as of 1 March 2024 is 7. The pillar scores are Audit: 3; Board: 6; Shareholder rights: 8; Compensation: 9.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.